---
title: "Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem."
description: "Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251688569.md"
published_at: "2025-08-05T17:45:15.000Z"
---

# Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem.

> Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.

Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.

### Related Stocks

- [HIMS.US - Hims & Hers Health](https://longbridge.com/en/quote/HIMS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 期权热点｜上周五 HIMS 涨 3%，部分看涨期权飙升 250% | 美东时间 02 月 13 日，HIMS 期权总成交 167327 张，看涨期权占比 68%，看跌期权占比 31%。 | [Link](https://longbridge.com/en/news/276030158.md) |
| 早盘趋势｜Hims & Hers Health 连续回踩，短线资金要抢反弹了吗？ | Hims & Hers Health（HIMS.US）昨夜承压继续下探，数字健康板块本周明显资金流出，但已经靠近关键技术支撑位，场内短线交易员们悄悄互问 “反弹资金是不是要来了？” 近期公司无重大战略消息，无新融资、并购、合作亮点，行业关注 | [Link](https://longbridge.com/en/news/272316089.md) |
| 期权热点｜上周五 NBIS 大涨 9%，部分看涨期权飙升 378% | 美东时间 02 月 13 日，Nebius 期权总成交 179098 张，看涨期权占比 71%，看跌期权占比 28%。 | [Link](https://longbridge.com/en/news/276030151.md) |
| FDA 的打击行动重塑了 Wegovy 的竞争格局，并增加了诺和诺德投资者的风险 | FDA 对诺和诺德公司 Wegovy 的误导性广告的打击加大了对 GLP-1 营销的审查，导致来自仿制药替代品的竞争减少。这一监管变化发生在诺和诺德面临美国定价压力可能导致销售下降的背景下。虽然 FDA 的行动可能在短期内支持 Wegovy | [Link](https://longbridge.com/en/news/275899622.md) |
| 港股异动：澜起科技涨 15.78%，花旗看好 AI 增长潜力，摩根大通增持助力股价攀升 | 澜起科技涨 15.78%；华虹半导体涨 1.57%，成交额达到 4.31 亿港币；中芯国际跌 0.36%，成交额达到 3.68 亿港币；兆易创新涨 14.27%，成交额达到 2.75 亿港币；豪威集团涨 0.79%，市值达到 1286 亿港 | [Link](https://longbridge.com/en/news/276028521.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.